» Articles » PMID: 37047636

Mineral Metabolism in Children: Interrelation Between Vitamin D and FGF23

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 13
PMID 37047636
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast growth factor 23 (FGF23) was identified at the turn of the century as the long-sought circulating phosphatonin in human pathology. Since then, several clinical and experimental studies have investigated the metabolism of FGF23 and revealed its relevant pathogenic role in various diseases. Most of these studies have been performed in adult individuals. However, the mineral metabolism of the child is, to a large extent, different from that of the adult because, in addition to bone remodeling, the child undergoes a specific process of endochondral ossification responsible for adequate mineralization of long bones' metaphysis and growth in height. Vitamin D metabolism is known to be deeply involved in these processes. FGF23 might have an influence on bones' growth as well as on the high and age-dependent serum phosphate concentrations found in infancy and childhood. However, the interaction between FGF23 and vitamin D in children is largely unknown. Thus, this review focuses on the following aspects of FGF23 metabolism in the pediatric age: circulating concentrations' reference values, as well as those of other major variables involved in mineral homeostasis, and the relationship with vitamin D metabolism in the neonatal period, in vitamin D deficiency, in chronic kidney disease (CKD) and in hypophosphatemic disorders.

Citing Articles

Mendelian randomization analyses explore the effects of micronutrients on different kidney diseases.

Shi C, Cao H, Zeng G, Wu H, Wang Y Front Nutr. 2024; 11:1440800.

PMID: 39346645 PMC: 11428537. DOI: 10.3389/fnut.2024.1440800.


FGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia.

Bhatia S, Malhotra P, Poole K, Malaviya A BMJ Case Rep. 2024; 17(8).

PMID: 39122377 PMC: 11409360. DOI: 10.1136/bcr-2023-259439.


Editorial of Special Issue "The Role of Vitamin D in Human Health and Diseases 3.0".

Silvagno F, Bergandi L Int J Mol Sci. 2024; 25(13).

PMID: 39000277 PMC: 11241230. DOI: 10.3390/ijms25137170.


Emerging concepts on the FGF23 regulation and activity.

Rivoira M, Peralta Lopez M, Areco V, Diaz de Barboza G, Dionisi M, Tolosa de Talamoni N Mol Cell Biochem. 2024; 480(1):75-89.

PMID: 38581553 DOI: 10.1007/s11010-024-04982-6.


[Effect of recombinant human growth hormone on serum Klotho and fibroblast growth factor 23 in children with idiopathic short stature].

Dong H, Li M, Sun M, Zhou R, Zhang X, Cheng Y Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(11):1143-1149.

PMID: 37990459 PMC: 10672957. DOI: 10.7499/j.issn.1008-8830.2306105.

References
1.
Fischer D, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G . Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012; 49(Pt 6):546-53. DOI: 10.1258/acb.2012.011274. View

2.
Ma Y, Samaraweera M, Cooke-Hubley S, Kirby B, Karaplis A, Lanske B . Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization. Endocrinology. 2014; 155(5):1596-605. PMC: 3990847. DOI: 10.1210/en.2013-2061. View

3.
Kovacs C . Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones. Physiol Rev. 2014; 94(4):1143-218. DOI: 10.1152/physrev.00014.2014. View

4.
Imel E, Glorieux F, Whyte M, Munns C, Ward L, Nilsson O . Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019; 393(10189):2416-2427. PMC: 7179969. DOI: 10.1016/S0140-6736(19)30654-3. View

5.
Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K . Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2009; 95(2):578-85. PMC: 2840849. DOI: 10.1210/jc.2009-1603. View